Tumor Suppressor P53: from Engaging DNA to Target Gene Regulation

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2020 Aug 16

PMID 32797160

Citations 38

Authors

Morgan A Sammons

Thuy-Ai T Nguyen

Simon S McDade

Martin Fischer

Affiliations

Soon will be listed here.

Abstract

The p53 transcription factor confers its potent tumor suppressor functions primarily through the regulation of a large network of target genes. The recent explosion of next generation sequencing protocols has enabled the study of the p53 gene regulatory network (GRN) and underlying mechanisms at an unprecedented depth and scale, helping us to understand precisely how p53 controls gene regulation. Here, we discuss our current understanding of where and how p53 binds to DNA and chromatin, its pioneer-like role, and how this affects gene regulation. We provide an overview of the p53 GRN and the direct and indirect mechanisms through which p53 affects gene regulation. In particular, we focus on delineating the ubiquitous and cell type-specific network of regulatory elements that p53 engages; reviewing our understanding of how, where, and when p53 binds to DNA and the mechanisms through which these events regulate transcription. Finally, we discuss the evolution of the p53 GRN and how recent work has revealed remarkable differences between vertebrates, which are of particular importance to cancer researchers using mouse models.

Citing Articles

Gene regulation by convergent promoters.

Wiechens E, Vigliotti F, Siniuk K, Schwarz R, Schwab K, Riege K Nat Genet. 2025; 57(1):206-217.

PMID: 39779959 PMC: 11735407. DOI: 10.1038/s41588-024-02025-w.

Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.

Ramli I, Cheriet T, Posadino A, Giordo R, Fenu G, Chukwuemeka Nwachukwu K EXCLI J. 2025; 23:1397-1439.

PMID: 39764218 PMC: 11701300. DOI: 10.17179/excli2024-7791.

High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic Adenocarcinoma.

Klein S, Bozko M, Toenniessen A, Rangno D, Bozko P Int J Mol Sci. 2024; 25(22).

PMID: 39596373 PMC: 11594790. DOI: 10.3390/ijms252212307.

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).

Tornesello M Int J Mol Med. 2024; 55(1).

PMID: 39450536 PMC: 11554381. DOI: 10.3892/ijmm.2024.5448.

Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.

Ikliptikawati D, Makiyama K, Hazawa M, Wong R Int J Mol Sci. 2024; 25(13).

PMID: 39000572 PMC: 11242911. DOI: 10.3390/ijms25137465.

References

Valente L, Gray D, Michalak E, Pinon-Hofbauer J, Egle A, Scott C . p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013; 3(5):1339-45. DOI: 10.1016/j.celrep.2013.04.012. View

Rutkowski R, Hofmann K, Gartner A . Phylogeny and function of the invertebrate p53 superfamily. Cold Spring Harb Perspect Biol. 2010; 2(7):a001131. PMC: 2890203. DOI: 10.1101/cshperspect.a001131. View

Tugrul M, Paixao T, Barton N, Tkacik G . Dynamics of Transcription Factor Binding Site Evolution. PLoS Genet. 2015; 11(11):e1005639. PMC: 4636380. DOI: 10.1371/journal.pgen.1005639. View

Huang J, Dorsey J, Chuikov S, Zhang X, Jenuwein T, Reinberg D . G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010; 285(13):9636-9641. PMC: 2843213. DOI: 10.1074/jbc.M109.062588. View

Sarosiek K, Fraser C, Muthalagu N, Bhola P, Chang W, McBrayer S . Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell. 2016; 31(1):142-156. PMC: 5363285. DOI: 10.1016/j.ccell.2016.11.011. View

Ma Q, Yang F, Mackintosh C, Jayani R, Oh S, Jin C . Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells. Cell Rep. 2020; 31(3):107532. DOI: 10.1016/j.celrep.2020.107532. View

Schlereth K, Heyl C, Krampitz A, Mernberger M, Finkernagel F, Scharfe M . Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions. PLoS Genet. 2013; 9(8):e1003726. PMC: 3744428. DOI: 10.1371/journal.pgen.1003726. View

Neph S, Vierstra J, Stergachis A, Reynolds A, Haugen E, Vernot B . An expansive human regulatory lexicon encoded in transcription factor footprints. Nature. 2012; 489(7414):83-90. PMC: 3736582. DOI: 10.1038/nature11212. View

Kaiser A, Attardi L . Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ. 2017; 25(1):93-103. PMC: 5729531. DOI: 10.1038/cdd.2017.171. View

10.

Korkmaz G, Lopes R, Ugalde A, Nevedomskaya E, Han R, Myacheva K . Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat Biotechnol. 2016; 34(2):192-8. DOI: 10.1038/nbt.3450. View

11.

Donehower L, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M . Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019; 28(5):1370-1384.e5. PMC: 7546539. DOI: 10.1016/j.celrep.2019.07.001. View

12.

Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T . GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017; 2017. PMC: 5467550. DOI: 10.1093/database/bax028. View

13.

Melo C, Drost J, Wijchers P, van de Werken H, de Wit E, Vrielink J . eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell. 2013; 49(3):524-35. DOI: 10.1016/j.molcel.2012.11.021. View

14.

Guan B, Wang T, Shih I . ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011; 71(21):6718-27. PMC: 3206175. DOI: 10.1158/0008-5472.CAN-11-1562. View

15.

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

16.

Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T . Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife. 2016; 5. PMC: 5114012. DOI: 10.7554/eLife.19317. View

17.

Sahu G, Wang D, Chen C, Zhurkin V, Harrington R, Appella E . p53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element. J Biol Chem. 2009; 285(2):1321-32. PMC: 2801259. DOI: 10.1074/jbc.M109.081182. View

18.

Wang J, Zhuang J, Iyer S, Lin X, Whitfield T, Greven M . Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res. 2012; 22(9):1798-812. PMC: 3431495. DOI: 10.1101/gr.139105.112. View

19.

Barlev N, Liu L, Chehab N, Mansfield K, Harris K, Halazonetis T . Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2002; 8(6):1243-54. DOI: 10.1016/s1097-2765(01)00414-2. View

20.

Min S, Kim K, Kim S, Cho H, Lee Y . Chromatin-remodeling factor, RSF1, controls p53-mediated transcription in apoptosis upon DNA strand breaks. Cell Death Dis. 2018; 9(11):1079. PMC: 6197202. DOI: 10.1038/s41419-018-1128-2. View